Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT00608920 Completed - Clinical trials for Adenocarcinoma of the Prostate

Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping

SPECT
Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the planning of radiation treatment of prostate cancer patient can be made more precise by comparing currently planning techniques to an imaging technique called SPECT.

NCT ID: NCT00607932 Completed - Prostate Cancer Clinical Trials

Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer

Start date: March 2005
Phase: N/A
Study type: Interventional

RATIONALE: Eating a diet high in vegetables may lower the risk of some types of cancer. Brassica vegetables (such as cabbages, kale, broccoli, Brussels sprouts, and cauliflower) and indole-3-carbinol (a substance found in cruciferous vegetables) may help lower the risk of prostate cancer recurrence. PURPOSE: This randomized clinical trial is studying the side effects and how well Brassica vegetables work compared with indole-3-carbinol in treating patients with PSA recurrence after surgery for prostate cancer.

NCT ID: NCT00605488 Completed - Breast Cancer Clinical Trials

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

Start date: April 25, 2006
Phase: N/A
Study type: Interventional

See where the dye-like material (FACBC) goes in your body and how long it stays in your body. See how much of the dye-like material is picked up by your tumor Compare the FACBC pictures with other pictures (such as FDG PET scan) that were obtained as part of your standard imaging evaluation.

NCT ID: NCT00604526 Completed - Prostate Cancer Clinical Trials

High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy

Start date: September 2006
Phase: Phase 1
Study type: Interventional

High dose rate (HDR) brachytherapy is a form of radiation treatment using temporary radioactive seeds. This is done by placing very tiny catheters or tubes into the prostate and then inserting temporary radioactive seeds, called Iridium 192, through these catheters. HDR brachytherapy gives precise radiation to the prostate with less radiation given to the normal tissues near the prostate. For patients who have been treated with external beam radiation to the prostate before, HDR brachytherapy can give radiation again to the prostate without exposing the normal tissues around the prostate to significantly more radiation. This may be safer than giving external beam radiation again. The purpose of this study is to test the safety of high dose rate temporary brachytherapy (HDR) for prostate cancer that has come back after external beam radiation. We want to find out what effects, good and/or bad, the treatment has on you and your recurrent prostate cancer.

NCT ID: NCT00600535 Completed - Prostate Neoplasms Clinical Trials

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Start date: July 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.

NCT ID: NCT00599313 Completed - Clinical trials for Metastatic Prostate Cancer

Phase II Sunitinib Prog Met AIPC

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

NCT ID: NCT00598312 Completed - Prostate Cancer Clinical Trials

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

Start date: April 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for Injectable Suspension 22.5 mg in reducing serum testosterone to castrate levels in patients with prostate cancer.

NCT ID: NCT00596895 Completed - Clinical trials for Biochemical Recurrent Prostate Cancer

Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer

Start date: November 2003
Phase: Phase 2
Study type: Interventional

Primary Outcome Measures: Decrease in rate of serum PSA rise Secondary Outcome Measures: Adherence to treatment regimens Quality of life as assessed by FACT-P at baseline and at 12 months of treatment Modulation of serum testosterone,isoflavone metabolites, and cholesterol Estimated Enrollment: 27 Study Start Date: November 2003 Estimated Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)

NCT ID: NCT00590993 Completed - Prostate Cancer Clinical Trials

Magnetic Resonance Imaging and Spectroscopy of the Prostate

Start date: December 2000
Phase:
Study type: Observational

Past studies have shown that MRI is useful for staging prostate cancer. This study will use magnetic resonance spectroscopic imaging (MRSI) to obtain more information. MRSIs with MRIs help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. This study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.

NCT ID: NCT00590213 Completed - Prostate Cancer Clinical Trials

Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX

COMART
Start date: June 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain. Patients will receive either prophylactic radiotherapy to the breast at a dose of 12Gy (as two fractions of 6 Gy in consecutives days), or will not receive any radiotherapy prior to commencing CASODEX 150mg monotherapy.